Education
About Us
Working with TipRanks
Follow Us
Lenz Therapeutics, Inc. (LENZ)
:LENZ
Total Valuation
LENZ Therapeutics has a market cap or net worth of $980.05M. The enterprise value is ―.
Market Cap$980.05M
Enterprise Value―
Share Statistics
LENZ Therapeutics has 28,146,154 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,146,154
Owned by Insiders16.32%
Owned by Institutions0.18%
Financial Efficiency
LENZ Therapeutics’s return on equity (ROE) is -0.68 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.68
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)-0.40
Revenue Per Employee0.00
Profits Per Employee-20.78M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of LENZ Therapeutics is -0.81. LENZ Therapeutics’s PEG ratio is -0.43.
PE Ratio-0.81
PS Ratio0.00
PB Ratio3.41
Price to Fair Value0.55
Price to FCF-11.80
Price to Operating Cash Flow-11.73
PEG Ratio-0.43
Income Statement
In the last 12 months, LENZ Therapeutics had revenue of 0.00 and earned -124.65M in profits. Earnings per share was -15.30.
Revenue0.00
Gross Profit-2.41M
Operating Income-73.11M
Pretax Income-124.65M
Net Income-124.65M
EBITDA-122.24M
Earnings Per Share (EPS)-15.30
Cash Flow
In the last 12 months, operating cash flow was -59.39M and capital expenditures -468.00K, giving a free cash flow of -59.86M billion.
Operating Cash Flow-59.39M
Free Cash Flow-59.86M
Free Cash Flow per Share-2.13
Dividends & Yields
LENZ Therapeutics pays an annual dividend of $7.21, resulting in a dividend yield of ―
Dividend Per Share$7.21
Dividend Yield―
Payout Ratio-21.57%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.71
52-Week Price Change74.71%
50-Day Moving Average29.31
200-Day Moving Average27.49
Relative Strength Index (RSI)65.48
Average Volume (3m)299.26K
Important Dates
LENZ Therapeutics upcoming earnings date is Aug 13, 2025, After Close (Confirmed).
Last Earnings DateMay 7, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend DateMar 22, 2024
Financial Position
LENZ Therapeutics as a current ratio of 39.20, with Debt / Equity ratio of 0.68%
Current Ratio39.20
Quick Ratio39.20
Debt to Market Cap<0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, LENZ Therapeutics has paid -124.65M in taxes.
Income Tax-124.65M
Effective Tax Rate1.00
Enterprise Valuation
LENZ Therapeutics EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.66.
EV to Sales0.00
EV to EBITDA-0.54
EV to Free Cash Flow-0.66
EV to Operating Cash Flow-0.74
Balance Sheet
LENZ Therapeutics has $209.03M in cash and marketable securities with $1.38M in debt, giving a net cash position of -$207.65M billion.
Cash & Marketable Securities$209.03M
Total Debt$1.38M
Net Cash-$207.65M
Net Cash Per Share-$7.38
Tangible Book Value Per Share$22.54
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for LENZ Therapeutics is $45.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$45.00
Price Target Upside29.24% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast68.93%